Two days ahead of an FDA advisory committee meeting focused on Onyx Pharmaceuticals Inc.'s new drug application for Kyprolis (carfilzomib), briefing documents highlighted the agency's concern over severe cardiac toxicities and the possibility that the second-generation proteasome inhibitor may not offer an advantage over existing multiple myeloma therapies.